Assistant Professor
4111 Rennebohm Hall
Phone: 608-890-2150
Fax: 608-262-5345
pcmarker@pharmacy.wisc.edu
Email Paul Marker
Dr. Marker received his B.A. degree from Grinnell College in 1991 and his Ph.D. in developmental biology from Stanford University in 1998. He conducted postdoctoral research on the molecular basis of prostate development and prostate cancer progression with Gerald Cunha at the University of California San Francisco from 1998-2002. From 2002-2007, he was an Assistant Professor at the University of Minnesota. He moved to the School of Pharmacy in the Fall of 2007.
Research in the Marker laboratory is focused on understanding the biology of the prostate gland at the molecular level. Interest in understanding the biology of the prostate is driven both by the fascinating nature of the developmental processes that function during organogenesis of the prostate and by the high incidence in humans of prostatic diseases including prostatic adenocarcinoma and benign prostatic hyperplasia. The Marker lab is particularly interested in the role of intercellular communication between epithelial and mesenchymal/stromal cells during prostatic branching morphogenesis and during the progression of prostate cancer.
Current projects in the Lab include investigation of the roles of Fibroblast growth factor receptor 2 (Fgfr2) during prostatic development and cancer progression. Large scale sequencing and whole-genome association studies have shown that Fgfr2 is both commonly mutated in human cancers, and single nucleotide polymorphisms in Fgfr2 increase the risk for developing cancer. Data from the Marker lab and others has also shown that the Fgfr2 is a critical mediator of early development in the prostate. Ongoing research in the Marker lab is focused on understanding the mechanisms of Fgfr2 action in the prostate both during mouse development and in human prostate cancer. A second project in the Marker lab is a forward genetic screen in mice to identify new genes involved in prostate cancer progression using transposon-mediated insertional mutagenesis. A secondary screen is used to validate the importance of candidate genes identified using the mouse model by examining the human orthologues of the candidates for altered expression in human prostate cancers. This project has already identified new candidate oncogenes that are also over-expressed in human prostate cancers. Ongoing studies include continued screens for novel prostate cancer genes and functional evaluation of candidate genes to determine their roles in prostate cancer initiation and/or progression.